在骨髓瘤恶性瘤中使用Tagraxofusp
Antonella Bruzzese1, Enrica Antonia Martino1, Caterina Labanca1
1Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy.
Hematological oncology
|October 17, 2023
概括
Tagraxofusp有效治疗形血细胞突瘤 (BPDCN),并正在探索其他CD123阳性髓状瘤. 组合疗法可以通过向DPH1表达来克服抗性.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 针对CD123的融合蛋白Tagraxofusp在治疗侵袭性骨髓瘤恶性瘤方面表现有前途.
- 囊性等离子细胞状树突细胞瘤 (BPDCN) 往往对常规化疗不耐药.
研究的目的:
- 审查tagraxofusp在BPDCN和其他CD123阳性髓状瘤中的作用.
- 探索tagraxofusp治疗的组合策略和抵抗机制.
主要方法:
- 对tagraxofusp的临床研究和研究的审查.
- 分析tagraxofusp的作用机制和抵抗路径.
- 研究组合疗法,包括tagraxofusp与azacitidine和venetoclax.
主要成果:
- 在BPDCN中,Tagraxofusp显示出高疗效和可接受的安全性,从而获得了监管部门的批准.
- 目前,Tagraxofusp正在对其他CD123阳性骨髓性瘤进行研究,组合策略特别感兴趣.
- 阿扎西提丁可以逆转DPH1下调,可能克服tagraxofusp耐药性.
结论:
- 塔格拉克索福斯普是BPDCN的成功治疗剂,并对其他CD123阳性髓状瘤具有潜力.
- 组合疗法对于扩大tagraxofusp的效用和管理耐药性至关重要.
- 目前正在进行的试验正在评估tagraxofusp在各种骨髓瘤恶性瘤中.
相关概念视频
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
170
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
170
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
122
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
122
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
148
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
148
01:24Cystic Fibrosis: Management
173
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
173